ReviewFrontiers in pharmacology2022
Mechanistic insights into the role of plant polyphenols and their nano-formulations in the management of depression.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Neuroprotective effects of icariin in animal models of depression and anxiety: a systematic review of preclinical studies.BMC complementary medicine and therapies · 2026Pooled it
- Research progress and hotspots of the impact of Mediterranean diet on brain health from 2005 to 2025: a bibliometric and visualization analysis.Frontiers in nutrition · 2026Pooled it
- Preliminary clinical and electrophysiological findings of NAc/ALIC deep brain stimulation strategy for treatment-resistant depression.iScience · 2026Article
- Validation, quantification, and molecular docking of isolated eupalitin 3-O-β-D-galactopyranoside in Boerhavia diffusa Linn for hepatoprotective and immunomodulatory activity.Scientific reports · 2026Article
- Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy.Frontiers in nutrition · 2026Review
- Polyherbal Therapy Restores Sensorimotor Function in Chronic Stress-induced Oxidative Damage.Archives of Razi Institute · 2025Article
- Paeoniflorin and depression: a comprehensive review of underlying molecular mechanisms.Metabolic brain disease · 2025Review
- Phytochemicals Modulate Biosynthesis and Function of Serotonin, Dopamine, and Norepinephrine for Treatment of Monoamine Neurotransmission-Related Psychiatric Diseases.International journal of molecular sciences · 2025Review
- Integrative approaches to depression in end-stage renal disease: insights into mechanisms, impacts, and pharmacological strategies.Frontiers in pharmacology · 2025Review
- Editorial: Noninvasive brain stimulation: a promising approach to study and improve emotion regulation.Frontiers in behavioral neuroscience · 2025Article
- Cinnamic Acid, Perillic Acid, and Tryptophan Metabolites Differentially Regulate Ion Transport and Serotonin Metabolism and Signaling in the Mouse Ileum In Vitro.International journal of molecular sciences · 2024Article
- Dietary Phenolic Compounds: Their Health Benefits and Association with the Gut Microbiota.Antioxidants (Basel, Switzerland) · 2023Review
- Effects of (S)-ketamine on depression-like behaviors in a chronic variable stress model: a role of brain lipidome.Frontiers in cellular neuroscience · 2023Article
- Hyperglycemia-associated Alzheimer's-like symptoms and other behavioral effects attenuated byFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a condition characterized by low mood and an aversion to activity, that causes behavioral problems, poor quality of life and limits daily life activities. It is considered as the fourth leading cause of disability worldwide. Selective Serotonin Reuptake Inhibitors (SSRIs) Monoamine Oxidase (MAO) inhibitors, Tricyclic Antidepressants (TCAs), and atypical antidepressants are some of the conventional medications used to treat depression. However, only about half of patients with major depressive disorder (MDD) respond effectively to first-line antidepressant therapy. Additionally, there are a number of drawbacks to standard antidepressants, such as anti-cholinergic side effects, drug-drug interactions, and food-drug interactions, which prompts researchers to look at alternative approaches to the treatment of depression. Medicinal plants and their metabolites are extensively tested for their efficacy against depression. Electronic databases such as Google scholar, Science Direct, SciFinder and PubMed were used to search relevant literature on the role of polyphenols in depression. Plants-derived Polyphenols represent a major class of compounds extensively distributed in plants. Number of polyphenols have demonstrated antidepressant activity, among which berberine, piperine, curcumin, naringenin, ascorbic acid and ginsenosides are extensively evaluated. The medicinal plants and their derived compounds mediated synthesized green nanoparticles have also exhibited considerable efficacy in the management of depression. The therapeutic effects of these phytochemicals is mediated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.